Behcet’s syndrome also known as behcet’s disease (BD) is an autoimmune disorder, in which the body's immune system destroys some of its own healthy cells. It is an inflammatory and non-contagious disease that can affect several areas of the body. The cause of this condition is unknown, however it is thought to be hereditary in nature. Behcet’s syndrome is diagnosed when there are at least three instances of mouth sores in a year, as well as at least two genital sores, eye irritation, skin sores, and a positive skin prick test. The symptoms of behcet’s syndrome differ from person to person. Its symptoms are known to be caused by inflammation of the blood vessels (vasculitis). The disease can affect arteries and veins of various sizes, causing them to swell and cause damage throughout the body. The mouth, eyes, genital regions, eyes, skin, stomach, brain, joints, and other areas are the most likely to be affected by behcet's syndrome
Behcet’s syndrome is a relapsing-remitting vasculitis with an undefined cause. It is a complicated condition, hence, it has the potential to impact nearly all organ systems in the human body. As behcet’s syndrome is life-threatening condition, it is important to develop novel drugs. Emergence of new treatments and medications are under pipeline. Hence, several companies such as Novartis AG, AbbVie Inc., and Celgene Corporation are involved in research and development of advance drugs to reduce the severity of behcet’s syndrome. In addition, this is expected to create vast opportunities for market growth in the forecast period.
Global Behcet’s Syndrome Market – Dynamics
Rising management therapies to reduce the worsening of the behcet’s syndrome is anticipated to boost the market growth in the forecast period. For instance, in July 2021, according to Dove Medical Press, the syndrome has a heterogeneous nature, its treatment and management differentiates as per the type of involvement. Joint involvement and mucocutaneous in behcet’s syndrome patients do not result in a permanent damage with proper manifestation. In the behcet’s syndrome, conventional therapy is the primary option. Immunosuppressive therapy, on the other hand, is required in individuals with significant organ involvement. Conventional treatment for management of behcet’s syndrome includes colchicine, azathioprine, cyclosporine-A, and cyclophosphamide to decrease the seriousness of disease is projected to drive the market growth during the forecast period.
Increasing clinical trial studies for evaluating the safety and efficacy of the drugs is estimated to drive the global behcet’s syndrome market growth during the forecast period. For instance, in May 2020, as per the U.S. National Liabraby of Medicine, a study is conducted to evaluate the efficacy and safety of Amgen’s apremilast (CC-10004) in the treatment of behcet’s syndrome. In the treatment of ulcers in the mouth with behcet's syndrome, apremilast is used. Apremilast is approved for adults with oral ulcers associated with behcet’s syndrome, which is anticipated to drive the market growth during the forecast period.
Global Behcet’s Syndrome Market – Regional Insights
North America is anticipated to hold dominate market share the behcet’s syndrome market growth during the forecast period owing to increasing use of different diagnostic criteria for behcet’s syndrome. For instance, in November 2017, according to European Journal of Rheumatology, new international criteria for Behçet's Disease (ICBD) were suggested, emphasizing oral, genital, and ophthalmic involvement and allowing for the incorporation of vascular and neurological involvement as a reference for behcet’s syndrome diagnosis. Neurologic and gastrointestinal symptoms were observed in a considerably larger percentage of individuals in the United States.
Asia pacific is anticipated to witness lucrative market growth during the forecast period owing to increasing prevalence of the behcet’s syndrome. It is observed commonly among populations living in Japan and China. It is frequently noted between the 30th and 45th degree latitudes populations. For instance, according to a research study published in May 2021, in Journal of Clinical Rheumatology and Immunology, in East Asia, the prevalence is stated to be 16/100,000 in Japan, 35/100,000 in Korea, and 14/100,000 in China, which is expected to propel the behcet’s syndrome market growth during the forecast period in the region.
Global Behcet’s Syndrome Market – Taxonomy
By Treatment Type:
By Distribution Channel:
Global Behcet’s Syndrome Market – Competitive landscape
Key players operating in the global behcet’s syndrome market include Novartis AG, AbbVie Inc., and Celgene Corporation among others.